Abstract
Calcium antagonistic drugs have been recognized as useful antiarrhythmic agents for approximately a decade. More recently, however, their vascular effects have been shown to be of potential therapeutic and pharmacological interest, especially in the treatment of angina pectoris involving coronary arterial spasm and possibly also of hypertension. The present survey is dealing with the circulatory changes of the calcium antagonists, describing the influence of the drugs on the systemic and coronary circulation, as well as on special vascular beds like the renal and cerebral circulatory tracts. The influence of the calcium antagonistic agents on vascular smooth muscle at a cellular level is the main subject of the present article. The calcium antagonists inhibit the influx of calcium ions into the cell. Accordingly, they prevent the vasoconstriction, induced by the stimulation of vascularα 2-adrenoceptors. However, the calcium antagonists do not blockα 2-adrenoceptors as such, but they prevent the stimulation of the contractile proteins. This type of interaction has been demonstrated in various animal species for a variety of calcium antagonists on the one hand and for several selective or non-selectiveα 2-adrenoceptor stimulants on the other hand. The vasodilator effect of calcium antagonists may be explained by the selective inhibition of the vasoconstriction, induced by the stimulation ofα 2-adrenoceptors by endogenous (nor)adrenaline.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abboud, F.M. (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.
Bevan, J.A. (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.
Bing, R.J., M. Ohashi andT. Yamakawa (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.
Bohr, D.F. (1963)Science 139, 579–599.
Cambridge, D., M.J. Davey andR. Massingham (1977)Brit. J. Pharmacol. 59, 514P-515P.
Deth, R., andC. Van Breemen (1974)Pflugers Arch. Ges. Physiol. 348, 13–22.
Doxey, J.C., C.F.C. Smith andJ.M. Walker (1977)Brit. J. Pharmacol. 60, 91–96.
Fleckenstein, A. (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.
Fleckenstein, A., K. Nakayama, G. Fleckenstein-Grün andY.K. Byon (1975) In:Calcium Transport in Contraction and Secretion (Carafoli, E.,et al., Eds.). North-Holland Publishing Company, Amsterdam-Oxford, 555–566.
Godfraind, T., andA. Kaba (1972)Arch. Intern. Pharmocodyn. (Suppl.) 196, 35–36.
Godfraind, T., andR.C. Miller (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.
Goodman, F.R., andG.B. Weiss (1971)J. Pharmacol. Exp. Therap. 17, 415–425.
Grün, G., andA. Fleckenstein (1972)Arzneimittel-Forsch. 22, 334–344.
Hester, R.K., andO. Carrier (1977)Factors influencing vascular reactivity. Igaku-Shoin, Tokyo-New York, 96–105.
Kahan, A., S. Weber, B. Amor, L. Saporta, M. Hodara, M. DeGeorges (1981) VIIIth Int. Congress of Pharmacology, 1981, Abstr. nr. 1911, Tokyo, Japan.
Koch-Weser, J. (1976)New Engl. J. Med. 295, 320–323.
Kukovetz, W.R., G. Pöch andA. Wurm (1976) In:Ionic actions on vascular smooth muscle (Etz, E., Ed.). Springer-Verlag, Berlin, 124–131.
Lederballe Pedersen, O., N.J. Christensen andK.D. Rämsch (1980)J. Cardiov. Pharmacol. 2, 357–366.
Lefèvre-Borg, F., andI. Cavero (1982)Brit. J. Pharmacol., in press.
Meinertz, T., andH. Scholz (1969)Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmacol. 264, 281–282.
Meel, J.C.A. Van, A. De Jonge, B. Wilffert, H.O. Kalkman, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1981a)Eur. J. Pharmacol. 69, 205–208.
Meel, J.C.A. Van, A. De Jonge, H.O. Kalkman, B. Wilffert, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1981b)Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmacol. 316, 288–293.
Meel, J.C.A. Van, B. Wilffert, K. De Zoeten, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1982)Arch. Intern. Pharmacodyn., in press.
Mostbeck, A., K. Partsch andL. Perschl (1975)First International Nifedipine ‘Adalat’ Symposium, Tokyo (Hashimoto et al., Eds.). University of Tokyo Press, Tokyo, 136.
Olivari, M.T., C. Bartorelli, A. Polese, C. Fiorentini, P. Moruzzi andM.D. Guazzi (1979)Circulation 59, 1056–1062.
Schädler, M. (1967)Pflügers Arch. Ges. Physiol. 296, 70–90.
Singh, B.N., G. Eilrodt andC.T. Peter (1978)Drugs 15, 169–197.
Sitrin, M.D., andD.F. Bohr (1971)Am. J. Physiol. 220, 1124–1128.
Stoclet, J.C., andC. Lugnier (1978) In:Mechanisms of Vasodilatation (Vanhoutte, P.M., andI. Lensen, Eds.). S. Karger AG, Basel, 152–157.
Takenaka, T., T. Usada, T. Nomura, H. Maeno andT. Sato (1976)Arzneimittel-Forsch. 26, 2172–2178.
Tanaka, K., F. Gotoh, F. Muramatsu, Y. Fukuuchi, T. Amano, H. Okayasu andN. Suzuki (1980)Arzneimittel-Forsch. 30, 1494–1497.
Thuillez, C., andJ.F. Giudicelli (1981)Therapie 36, 107–121.
Towart, R. (1981)Circulation Res. 48, 650–657.
Vatner, S.F., T.H. Hintze andP. Macho (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.
Weitzell, R., T. Tanaka andK. Starke (1979)Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmacol. 308, 127–136.
Zsotér, T.T. (1980)Am. Heart J. 99, 805–810.
Zwieten, P.A. Van, andP.B.M.W.M. Timmermans (1980)Pharm. Weekbl. Sci. Ed. 2, 161–171.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Zwieten, P.A., Van Meel, J.C.A. & Timmermans, P.B.M.W.M. Vascular aspects of calcium antagonists. Pharmaceutisch Weekblad Scientific Edition 3, 1549–1559 (1981). https://doi.org/10.1007/BF02193433
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02193433